Search

Displaying results 2721 - 2730 of 4539 in total
  1. Drug

    OBE101

    go.drugbank.com/drugs/DB05080
    Experimental

    OBE101 is a new weight loss drug developed by Obecure Ltd. It is a new formulation that is based on the vertigo medication, Betahistine.

  2. Drug

    Grapiprant

    go.drugbank.com/drugs/DB12836
    InvestigationalVet approved

    [A39816] This class of drugs was defined in 2013 by the World Health Organization. … [L4766] Grapiprant has been approved in March 2016 by the FDA's Center for Veterinary Medicine as a non-cyclooxygenase inhibiting NSAID for veterinary use.[A39836]

  3. Drug

    Imlifidase

    go.drugbank.com/drugs/DB15258
    ApprovedInvestigational

    [A225836,A225921] Imlifidase is a cysteine protease and eliminates Fc-dependent effector functions such as CDC and ADCC by cleaving the heavy chains of human immunoglobulin G (IgG) antibodies.

  4. Drug

    Temanogrel

    go.drugbank.com/drugs/DB05227
    Investigational

    APD791 is intended to lower the risk of arterial thrombosis by reducing the amplification of platelet aggregation, arterial constriction and intimal hyperplasia mediated by serotonin. … APD791 is an oral anti-thrombotic drug candidate being evaluated in a Phase 1 clinical trial by Arena.

  5. Drug

    Cytisine

    go.drugbank.com/drugs/DB09028
    Investigational

    Recent Phase III clinical trials using Tabex (a brand of Cytisine marketed by Sopharma AD) have shown similar efficacy to varenicline, but at a fraction of the cost.

  6. Drug

    Polydatin

    go.drugbank.com/drugs/DB11263
    Approved

    It is shown to mediate a cytotoxic action on colorectal cancer cells by inducing cell arrest and apoptosis [A27229].

  7. Drug

    Rice bran oil

    go.drugbank.com/drugs/DB11293
    ApprovedInvestigational

    Rice bran oil is classified as an indirect additive used in food contact substances by the FDA.

  8. Drug

    Lisinopril

    go.drugbank.com/drugs/DB00722
    ApprovedInvestigational

    [A184853] It functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldosterone system.

  9. Drug

    Diphenoxylate

    go.drugbank.com/drugs/DB01081
    ApprovedIllicitInvestigational

    This medication is classified as a Schedule V under the Controlled Substances Act by the Food and Drug Administration (FDA) and the DEA in the United States when used in preparations.

  10. Drug

    Elesclomol

    go.drugbank.com/drugs/DB05719
    Investigational

    It is being developed by Synta Pharmaceuticals. … Elesclomol is a novel, injectable, drug candidate that kills cancer cells by elevating oxidative stress levels beyond a breaking point, triggering programmed cell death.